Abstract：
UNASSIGNED: The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine.
UNASSIGNED: This is a retrospective observational study of calls to New South Wales Poisons Information Centre between January 2014 and December 2022. We identified exposures to classical psychedelics within New South Wales Poisons Information Centre database and measured the annual number of exposures, source of call (hospital, health care worker, member of the public), co-ingested substances, clinical features and advice given.
UNASSIGNED: There were 737 calls related to relevant psychedelic exposures; 352 (47.8 per cent) to lysergic acid diethylamide, 347 (47.0 per cent) to psilocybin, 28 (3.8 per cent) to N,N-dimethyltryptamine, 4 (0.5 per cent) to ayahuasca, 4 (0.5 per cent) to mescaline and 2 (0.3 per cent) to ibogaine. Cases were predominantly male (77.2 per cent) and aged between 20 and 74 years (65.6 per cent). Psychedelic calls more than doubled from 45 in 2014 to 105 in 2022 and 625 (85 per cent) of all calls were either from or referred to hospital. Co-ingestion of psychedelics with another substance occurred in 249 (33.8 per cent) of calls and the most frequent clinical features related to single substance psychedelic exposures were hallucinations (27.6 per cent), gastrointestinal symptoms (21.7 per cent) and tachycardia (18.1 per cent). Seizures occurred in 2.9 per cent of single substance psychedelic exposures.
UNASSIGNED: Increasing incidence of psychedelic exposure calls, including those reporting significant toxicity, likely reflects increasing community use. This may in part be driven by increasing interest in psychedelic assisted psychotherapy trials subsequently increasing public awareness.
UNASSIGNED: Relatively high poisoning severity contrasts with safety within clinical trials of psychedelic assisted psychotherapy that may relate to the uncontrolled nature of community use which is mitigated within clinical trial environments. Education about safe use may be useful.
UNASSIGNED: This is a retrospective observational study of calls to New South Wales Poisons Information Centre between January 2014 and December 2022. We identified exposures to classical psychedelics within New South Wales Poisons Information Centre database and measured the annual number of exposures, source of call (hospital, health care worker, member of the public), co-ingested substances, clinical features and advice given.
UNASSIGNED: There were 737 calls related to relevant psychedelic exposures; 352 (47.8 per cent) to lysergic acid diethylamide, 347 (47.0 per cent) to psilocybin, 28 (3.8 per cent) to N,N-dimethyltryptamine, 4 (0.5 per cent) to ayahuasca, 4 (0.5 per cent) to mescaline and 2 (0.3 per cent) to ibogaine. Cases were predominantly male (77.2 per cent) and aged between 20 and 74 years (65.6 per cent). Psychedelic calls more than doubled from 45 in 2014 to 105 in 2022 and 625 (85 per cent) of all calls were either from or referred to hospital. Co-ingestion of psychedelics with another substance occurred in 249 (33.8 per cent) of calls and the most frequent clinical features related to single substance psychedelic exposures were hallucinations (27.6 per cent), gastrointestinal symptoms (21.7 per cent) and tachycardia (18.1 per cent). Seizures occurred in 2.9 per cent of single substance psychedelic exposures.
UNASSIGNED: Increasing incidence of psychedelic exposure calls, including those reporting significant toxicity, likely reflects increasing community use. This may in part be driven by increasing interest in psychedelic assisted psychotherapy trials subsequently increasing public awareness.
UNASSIGNED: Relatively high poisoning severity contrasts with safety within clinical trials of psychedelic assisted psychotherapy that may relate to the uncontrolled nature of community use which is mitigated within clinical trial environments. Education about safe use may be useful.
摘要：
近年来，某些经典迷幻药的全球使用有所增加，但对它们在澳大利亚的毒性范围知之甚少。我们的目标是描述对新南威尔士州毒物信息中心的电话，这些电话涉及对经典迷幻药的暴露，包括麦角酰二乙胺，psilocybin,N,N-二甲基色胺,ayahuasca,Mescaline和Ibogaine.
■这是一项回顾性观察研究，涉及2014年1月至2022年12月之间致电新南威尔士州毒物信息中心。我们在新南威尔士州毒药信息中心数据库中确定了经典迷幻药的暴露量，并测量了每年的暴露量，呼叫来源(医院，医护人员,公众成员)，共同摄入的物质，临床特点及建议。
■有737个与相关迷幻剂接触有关的电话；352个（47.8％）与麦角酰二乙胺有关，347（47.0％）至psilocybin，28（3.8％）至N，N-二甲基色胺,4（0.5％）至ayahuasca，4（0.5％）至mescaline，2（0.3％）至ibogaine。病例主要为男性(77.2%)，年龄在20至74岁之间(65.6%)。迷幻电话从2014年的45个增加到2022年的105个，增加了一倍以上，所有电话中有625个（85％）来自医院或转诊到医院。迷幻药与另一种物质的共同摄入发生在249例(33.8%)电话中，与单一物质迷幻药暴露相关的最常见临床特征是幻觉(27.6%)，胃肠道症状(21.7%)和心动过速(18.1%)。癫痫发作发生在单一物质迷幻剂暴露的2.9％中。
■迷幻暴露电话的发生率增加，包括那些报告重大毒性的，可能反映了社区使用的增加。这可能部分是由于对迷幻辅助心理治疗试验的兴趣增加，随后公众意识提高所致。
■在迷幻辅助心理治疗的临床试验中，相对较高的中毒严重程度与安全性形成对比，这可能与在临床试验环境中缓解的社区使用的不受控制的性质有关。关于安全使用的教育可能是有用的。
■这是一项回顾性观察研究，涉及2014年1月至2022年12月之间致电新南威尔士州毒物信息中心。我们在新南威尔士州毒药信息中心数据库中确定了经典迷幻药的暴露量，并测量了每年的暴露量，呼叫来源(医院，医护人员,公众成员)，共同摄入的物质，临床特点及建议。
■有737个与相关迷幻剂接触有关的电话；352个（47.8％）与麦角酰二乙胺有关，347（47.0％）至psilocybin，28（3.8％）至N，N-二甲基色胺,4（0.5％）至ayahuasca，4（0.5％）至mescaline，2（0.3％）至ibogaine。病例主要为男性(77.2%)，年龄在20至74岁之间(65.6%)。迷幻电话从2014年的45个增加到2022年的105个，增加了一倍以上，所有电话中有625个（85％）来自医院或转诊到医院。迷幻药与另一种物质的共同摄入发生在249例(33.8%)电话中，与单一物质迷幻药暴露相关的最常见临床特征是幻觉(27.6%)，胃肠道症状(21.7%)和心动过速(18.1%)。癫痫发作发生在单一物质迷幻剂暴露的2.9％中。
■迷幻暴露电话的发生率增加，包括那些报告重大毒性的，可能反映了社区使用的增加。这可能部分是由于对迷幻辅助心理治疗试验的兴趣增加，随后公众意识提高所致。
■在迷幻辅助心理治疗的临床试验中，相对较高的中毒严重程度与安全性形成对比，这可能与在临床试验环境中缓解的社区使用的不受控制的性质有关。关于安全使用的教育可能是有用的。
